SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Barter P)
 

Sökning: WFRF:(Barter P) > Achievement of comb...

Achievement of combined goals of low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol with three different statins: Results from VOYAGER

Karlson, Björn W., 1953 (författare)
Gothenburg University,Göteborgs universitet,Institutionen för medicin, avdelningen för molekylär och klinisk medicin,Institute of Medicine, Department of Molecular and Clinical Medicine
Toth, P. P. (författare)
Palmer, M. K. (författare)
visa fler...
Barter, P. J. (författare)
Nicholls, S. J. (författare)
visa färre...
 (creator_code:org_t)
Elsevier Ireland Ltd, 2014
2014
Engelska.
Ingår i: IJC Metabolic and Endocrine. - : Elsevier Ireland Ltd. - 2214-7624. ; 5, s. 61-66
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Guidelines suggest that the combination of low-density lipoprotein cholesterol (LDL-C) and non-high-density lipoprotein cholesterol (non-HDL-C) is the most clinically relevant goal for lipid-lowering treatments. Methods: Data from VOYAGER, an individual patient data meta-analysis including 32,258 patients from 37 clinical trials, was used to determine the percentage of patients reaching combined goals of LDL-C and non-HDL-C following treatment with simvastatin, atorvastatin, or rosuvastatin. Paired comparisons were made between each dose of rosuvastatin and the same or higher doses of simvastatin and atorvastatin. Results: Each dose of rosuvastatin brought significantly more patients to the combined goal of LDL-C <. 100. mg/dL and non-HDL-C <. 130. mg/dL than the same or double dose of atorvastatin; atorvastatin 80. mg was significantly superior to rosuvastatin 10. mg (all p. <. 0.001). Each dose of rosuvastatin helped significantly more patients reach the combined goal than any dose of simvastatin (all p. <. 0.001), except for rosuvastatin 10. mg versus simvastatin 80. mg (non-significant). Also, each dose of rosuvastatin helped significantly more patients to reach the combined goal of LDL-C <. 70. mg/dL and non-HDL-C <. 100. mg/dL than the same or double dose of atorvastatin (all p. <. 0.001). Every dose of rosuvastatin was significantly superior to all doses of simvastatin (all p. ≤. 0.020), except for rosuvastatin 10. mg versus simvastatin 40. mg and 80. mg (non-significant). Conclusions: Physicians' choice of statin and dose is important in helping patients achieve the combined LDL-C and non-HDL-C goals recommended in established guidelines.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Klinisk medicin (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Clinical Medicine (hsv//eng)

Nyckelord

Atorvastatin
Low-density lipoprotein cholesterol
Non-high-density lipoprotein cholesterol
Rosuvastatin
Simvastatin
apolipoprotein
high density lipoprotein cholesterol
hydroxymethylglutaryl coenzyme A reductase inhibitor
low density lipoprotein cholesterol
triacylglycerol
Article
atherosclerotic cardiovascular disease
body mass
cholesterol blood level
diabetes mellitus
dyslipidemia
enzymatic assay
human
meta analysis (topic)
nephelometry
randomized controlled trial (topic)

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Hitta mer i SwePub

Av författaren/redakt...
Karlson, Björn W ...
Toth, P. P.
Palmer, M. K.
Barter, P. J.
Nicholls, S. J.
Om ämnet
MEDICIN OCH HÄLSOVETENSKAP
MEDICIN OCH HÄLS ...
och Klinisk medicin
Artiklar i publikationen
IJC Metabolic an ...
Av lärosätet
Göteborgs universitet

Sök utanför SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy